Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014;18(3):149-52.
doi: 10.5114/wo.2014.43153. Epub 2014 Jun 18.

Trabectedin as a single agent and in combination with pegylated liposomal doxorubicin - activity against ovarian cancer cells

Agnieszka Marczak  1 , Marta Denel  1
Affiliations
Review

Trabectedin as a single agent and in combination with pegylated liposomal doxorubicin - activity against ovarian cancer cells

Agnieszka Marczak et al. Contemp Oncol (Pozn). 2014.

Abstract

Over 225 000 new cases of ovarian cancer are diagnosed each year. Symptoms are often vague, so most cases are detected when the disease is at an advanced stage. There is a need to find new drugs which will be able to treat ovarian cancer effectively. One of the most promising antineoplastic agents is trabectedin (Yondelis), derived from the marine tunicate Ecteinascidia turbinata, approved by the European Union in July 2007 for the treatment of soft-tissue sarcomas. This drug shows a mechanism of action based on the inhibition of the nucleotide excision repair system. Trabectedin shows anti-tumour activity in vitro and in vivo in ovarian, breast, prostate, renal, melanoma and non-small cell lung cancer cell lines. Trabectedin in combination with pegylated liposomal doxorubicin demonstrates synergistic antineoplastic activity.

Keywords: chemotherapy; ovarian cancer; pegylated liposomal doxorubicin; trabectedin.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Structure of trabectedin
See this image and copyright information in PMC

References

    1. Gentry-Maharaj A, Menon U. Screening for ovarian cancer in the general population. Best Pract Res Clin Obstet Gynaecol. 2012;26:243–56. - PubMed
    1. Zhang B, Cai FF, Zhong XY. An overview of biomarkers for the ovarian cancer diagnosis. Eur J Obstet Gynecol Reprod Biol. 2011;158:119–23. - PubMed
    1. Ng JS, Low JJ, Ilancheran A. Epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2012;26:337–45. - PubMed
    1. Pignata S, Cannella L, Leopardo D, Pisano C, Bruni GS, Facchini G. Chemotherapy in epithelial ovarian cancer. Cancer Lett. 2011;303:73–83. - PubMed
    1. Dąbrowski T. Hair loss as a consequence of cancer chemotherapy – physical methods of prevention. A review of the literature. Contemp Oncol (Pozn) 2011;15:95–101.

LinkOut - more resources